CJC-1295 with DAC (Drug Affinity Complex) is a modified tetrasubstituted growth hormone-releasing hormone (GHRH) analog engineered for extended duration of action. The DAC component (Drug Affinity Complex) enables covalent binding to serum albumin, significantly prolonging the peptide’s half-life and providing sustained stimulation of growth hormone and IGF-1 release. Our research-grade CJC-1295 with DAC is synthesized with precise molecular modifications for investigating prolonged endocrine effects in metabolic and growth studies.